Drug Profile
Research programme: somatostatin analogues - Ardana
Alternative Names: Somatostatin analogues research programme - ArdanaLatest Information Update: 25 Oct 2006
Price :
$50
*
At a glance
- Originator Ardana Bioscience
- Class
- Mechanism of Action Somatotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2002 Europeptides has been acquired from Zentaris AG by Ardana Bioscience
- 19 May 2000 Preclinical development for Cancer in France (Unknown route)